Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD/Safety of MW032 vs Xgeva in Healthy Adults
NCT04798326Phase 1Completed
- Sponsor
- Mabwell
- Start
- Jun 2019
- Primary completion
- Jan 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant human papillomavirus nonavalent vaccine in Giant Cell Tumor of Bone (GCTB) and bone metastasis (2 arms), sponsored by Mabwell. Primary endpoints: Area under the plasma concentration-time curve and Maximum serum concentration. Started Jun 2019; status: completed.
02
Drugs
recombinant human papillomavirus nonavalent vaccine
03
Conditions
Giant Cell Tumor of Bone (GCTB)bone metastasis
Beyond the preview
Go deeper on NCT04798326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798326.